User:13mjs21/sandbox

Welcome to your sandbox!

Link to Project Resource Page
Project Homepage and Resources

Practice Editing Here (Nov 15th in-class Wiki session work)

 * This is a place to practice clicking the "edit" button and practice adding references (via the citation button).

Task: Amyloidosis


 * 1) Find a peer-reviewed journal article on PubMed. Practice inserting your citation in the above space using the "cite" tool
 * 2) Choose one "B-level" medical article on Wikipedia from the following list: https://wp1.openzim.org/#/project/Medicine/articles?quality=B-Class&importance=High-Class
 * 3) Practice editing live on Wikipedia by finding a typo in the text or improving the clarity/readability of a sentence by adjusting a few words in a sentence.

Assignment # 3- please post an anonymous copy here!
13mjs21

1.      Proposed Changes

Wild-type transthyretin (ATTR) amyloidosis is being increasingly identified in the elderly, and is found in a quarter of elderly at postmortem. ATTR is found in 13-19% of people experiencing heart failure with preserved ejection fraction, making it a very common form of systemic amyloidosis

2.     Rationale for proposed change

After reviewing the Amyloidosis article, and honing in on the Epidemiology section it was clear that subtypes of Amyloidosis were explored, for example: details about AL and AA Amyloidosis were explained, but there was a lack there of information on ATTR or senile Amyloidosis. After doing research on subtypes of Amyloidosis, I came to understand that ATTR is one of the most common types, thus I felt there needed to be supporting information on the prevalence and population affected by ATTR. Lastly, the only evidence to support ATTR was from a dated article in 2008, and although the information I added was slightly different, I thought the information from the 2021 review would supplement the Epidemiology section with recent and important points.

Citation: Sidiqi, M. Hasib; Gertz, Morie A. (2021). "Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021". Blood Cancer Journal. 11 (90): 1. doi:10.1038/s41408-021-00483-7. Retrieved 10 November 2021.

3.  Area of controversy

One area of ambiguity is that the statistics that were changed were not ‘updated’, but rather supplemental information that explores the same point (the prevalence and symptomology associated with ATTR amyloidosis) was suggested as a proposed change. I believe that using one term throughout the article (ATTR rather than senile/ATTR/TTR) and using updated statistics helps the reader understand subtypes and prevalence of amyloidosis.

4.      Critique of source:

The source I chose was a systematic review article, published in 2021 that is focused on the diagnosis and treatment of Immunoglobulin Light Chain Amyloidosis. I specifically chose a recent review article because I know systematic reviews are rigorous and have a high level of evidence. This article is from the Blood Cancer Journal and details a lot about different treatment modalities for Amyloidosis, so potentially there could be some bias regarding treatment recommendations, especially if there is involvement of different drug/treatment representatives. However, I used more general data/information from this article, which would be less likely to be biased regarding pharmaceutical influence.

5.   Article improvement (1 marks): Please see the Amyloidosis Talk page for my contribution

16sa48

Proposed Addition: AA amyloidosis is caused by an increase in extracellular deposition of serum amyloid A (SAA) protein. SAA protein levels can rise in both direct and indirect manners, through infection, inflammation, and malignancies.

Rationale for proposed change: The change introduces additional clarity with regards to the AA subtype of amyloidosis. The previous reference regarding the epidemiology was published in 1997. Although the article was published in the New England Journal of Medicine, it is a literature review, not a systematic one, and thus may have omitted some sources when drawing conclusions. This new source is a 2019 systematic review and indicates updated and more comprehensive areas of origin for amyloidosis. As this is an addition, and not a subtraction or re-write of the existing information, it should not be controversial. The original 1997 article specifically refers to AA amyloidosis “in the west,” and as this systematic review only included articles written in English, Dutch, French, or German, it generally is referring to AA cases “in the west” as well.

Citation: Brunger, A. F., Nienhuis, H., Bijzet, J., & Hazenberg, B. (2020). Causes of AA amyloidosis: a systematic review. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 27(1), 1–12. https://doi.org/10.1080/13506129.2019.1693359

Critique of source: As this is a systematic review, it is reliant on the quality of sources that it draws conclusions from. Diagnosis of AA amyloidosis, and exclusion of additional possible underlying conditions can be difficult. AA amyloidosis was unable to be specifically diagnosed before 1980 due to the lack of specific antibodies for immunohistochemistry. However, this would be true of all literature and systematic reviews that discuss AA amyloidosis.

What to post on the Wikipedia article talk page (part of assignment 3)

 * This will also be covered on Nov 15th in class. Your group should use the below template to share an outline of your proposed improvements (including your new wording and citations). Article talk pages are not places to share your assignment answers. The Wikipedia community will be more interested in viewing your exact article improvement suggestions including where you plan to improve the article (which section), what wording you suggest, and the exact citation (Note: all citations must meet WP:MEDRS)
 * You will not be able to paste citations directly from your sandbox to talk pages (unless you are interested in editing/learning Wiki-code in the "source editing" mode). We suggest re-adding your citations on the talk page manually (using the cite button and populating the citation by pasting in the DOI, website, or PMID). You will have to repeat this process yet again when you edit the actual article live.
 * Talk Page Template: CARL Medical Editing Initiative/Fall 2021/Talk Page Template